Array-Based Gene Discovery with Three Unrelated Subjects Shows SCARB2/LIMP-2 Deficiency Causes Myoclonus Epilepsy and Glomerulosclerosis  by Berkovic, Samuel F. et al.
ARTICLE
Array-Based Gene Discovery with Three Unrelated
Subjects Shows SCARB2/LIMP-2 Deficiency
Causes Myoclonus Epilepsy and Glomerulosclerosis
Samuel F. Berkovic,1,2,3,* Leanne M. Dibbens,4,5 Alicia Oshlack,6 Jeremy D. Silver,6,7 Marina Katerelos,8
Danya F. Vears,1,2 Renate Lu¨llmann-Rauch,9 Judith Blanz,10 Ke Wei Zhang,1 Jim Stankovich,6,11
Renate M. Kalnins,3 John P. Dowling,12 Eva Andermann,13 Frederick Andermann,13 Enrico Faldini,14
Rudi D’Hooge,14 Lata Vadlamudi,1,2 Richard A. Macdonell,3 Bree L. Hodgson,4 Marta A. Bayly,4
Judy Savige,1 John C. Mulley,4,5,15 Gordon K. Smyth,6 David A. Power,3,8 Paul Saftig,16
and Melanie Bahlo6
Action myoclonus-renal failure syndrome (AMRF) is an autosomal-recessive disorder with the remarkable combination of focal glomer-
ulosclerosis, frequently with glomerular collapse, and progressivemyoclonus epilepsy associatedwith storagematerial in the brain. Here,
we employed a novel combination of molecular strategies to ﬁnd the responsible gene and show its effects in an animal model. Utilizing
only three unrelated affected individuals and their relatives, we used homozygosity mapping with single-nucleotide polymorphism
chips to localize AMRF. We then used microarray-expression analysis to prioritize candidates prior to sequencing. The disorder was
mapped to 4q13-21, and microarray-expression analysis identiﬁed SCARB2/Limp2, which encodes a lysosomal-membrane protein, as
the likely candidate. Mutations in SCARB2/Limp2 were found in all three families used for mapping and subsequently conﬁrmed in
two other unrelated AMRF families. The mutations were associated with lack of SCARB2 protein. Reanalysis of an existing Limp2 knock-
out mouse showed intracellular inclusions in cerebral and cerebellar cortex, and the kidneys showed subtle glomerular changes. This
study highlights that recessive genes can be identiﬁed with a very small number of subjects. The ancestral lysosomal-membrane protein
SCARB2/LIMP-2 is responsible for AMRF. The heterogeneous pathology in the kidney and brain suggests that SCARB2/Limp2 has
pleiotropic effects that may be relevant to understanding the pathogenesis of other forms of glomerulosclerosis or collapse and
myoclonic epilepsies.Introduction
Action myoclonus-renal failure syndrome (AMRF [MIM
254900]) is a lethal inherited form of progressive myoclo-
nus epilepsy associated with renal failure. It typically pres-
ents at 15–25 years with proteinuria evolving into renal
failure or with neurological symptoms (tremor, action
myoclonus, seizures, and later ataxia). The renal pathology
is of focal glomerulosclerosis, sometimes with features of
glomerular collapse. Brain pathology shows unusual and
uncharacterized storage material. Initially identiﬁed in
the French-Canadian isolate, the disorder has now been
recognized in many countries.1–3
The autosomal-recessive gene defect underlying AMRF
was unknown, and the lack of large pedigrees and lethality
of the disorder precluded a conventional mapping strategy.
Here, we identify a lysososmal-membrane gene responsible
for the diverse pathologies in the kidney and brain in thiscondition.We used a novel strategy on just three unrelated
affected subjects and compare the features of a knockout
mouse with the human disease.
Material and Methods
Clinical Samples
Three unrelated Australian families with a single AMRF proband
were used for identifying the gene. Case A was of Turkish-Cypriot
origin; her parents were ﬁrst cousins (Figure 1). Ancestors of fam-
ilies B and C came from different regions of Britain, and no in-
breeding loops were known for either family.2,3 Peripheral blood
lymphocytes were obtained by venepuncture for extraction of
DNA, and lymphoblastoid cell lines were established for RNA
and protein studies from cases A and B and selected relatives.
Case C was deceased, but stored brain tissue in parafﬁn blocks
was available for DNA extraction. Cases A and B underwent audio-
grams and electrophysiological investigations at ages 33 and 31,
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DNA samples from venous blood or postmortem tissue in previ-
ously reported Canadian AMRF cases2 and from families with a
variety of other hereditary nephropathies were obtained. Clinical
studies were approved by the Human Research Ethics Committee
of Austin Health.
Genotyping
All 12 individuals labeled with asterisk in Figure 1 were genotyped
with the Affymetrix XBA 50K (single-nucleotide polymorphism)
SNP chip with standard protocols and software settings at the
Australian Genome Research Facility (AGRF). We performed
genotyping by using the Affymetrix GCOS software, with the
Dynamic Model4 algorithm, with the default settings. DNA sam-
ples passed all quality-control checkpoints, and the call rate was
high (>96%) for ten of the samples. Two samples had lower call
rates of 86%. Data were assembled into LINKAGE5 style .dat and
.pre ﬁles with in-house programs. Mendelian errors were detected
and removedwith PEDCHECK,6 and errors akin to unlikely double
recombinants were found with MERLIN.7 Less than 0.5% of geno-
types were deemed erroneous and recoded as missing data.
Additionally, seven microsatellite markers were chosen with the
UCSC genome browser (May 2004 assembly), and samples were
genotyped at the AGRF.
Linkage Identical-by-Descent and Homozygous-
by-Descent Analysis
All analysis was carried out with either ALLEGRO8 or MERLIN.7
Pairwise linkage identical by descent (IBD) sharing probabilities
were calculated with MERLIN. Regions with homozygosity by
descent (HBD) sharing were identiﬁed with the most likely
inferred inheritance vector calculated by ALLEGRO.
Testing of Relatedness with GBIRP
Analysis with the software GBIRP9 was used to test for distant
cousin-type relationships. The multipoint algorithm tests a likeli-
hood ratio of an nth cousin-type relationship against a hypothesis
of no relationship, assuming linkage equilibrium. dth degree
relatives are expected to inherit a fraction 1/2d of their DNA IBD.
To prevent potential bias due to linkage disequilibrium, we used
a sparse subset of the total marker map, with each marker at a
distance of at least 300 kb to its neighbors. This map included
only 17% of available marker loci. Signiﬁcance of the test statistic
was calculated by simulation of genotype data for 10,000 pairs of
unrelated individuals.
Expression Arrays
RNAwas used for expression analysis from cases A and B and their
gender-matched siblings. Each of the four samples was split and
labeled and hybridized to two Affymerix U133 Plus2 arrays, giving
eight arrays in total. Microarray analysis was performed with
bioconductor packages10 for the R programming environment
(see Web Resources). We performed quality assessment with diag-
nostic plots by using the affy package, and all arrays were found to
be satisfactory. Background subtraction, normalization, and probe
summarization were done with gcrma.11 We analyzed expression
levels with genewise linear models with effects for the disease state
(unaffected or affected) and the family (A or B) by using the limma
package.12 The blocking introduced by the technical replication
was handled by the method of Smyth et al.13 Tests of signiﬁcance
were conducted with empirical Bayesmoderated t tests that ensure
stable inference even with small sample size.14 Initially, this was
done for the whole data set, and then we restricted the analysis
to the 98 probe sets (which correspond to the 66 genes) in the
mapped region of interest. Multiple testing adjustment was
performed with the false-discovery-rate method.15
Sequencing of SCARB2 DNA and RNA
Genomic DNA was extracted from peripheral blood with the
QIAamp DNA Blood Maxi Kit (QIAGEN). Genomic DNA was
also extracted from formalin ﬁxed parafﬁn-embedded tissue. The
tissue was sequentially rehydrated, and per sample size of
0.5 cm2 was incubated in 1 mg/ml proteinase K, 1% SDS, and ro-
tated at 37C for at least 4 hr. After two extractions with phenol
and chloroform and chloroform extraction, the DNA was ethanol
precipitated. We used direct sequencing of PCR products to screen
for mutations in the 12 exons and splice junctions of the SCARB2
gene. The NCBI accession number of the SCARB2 mRNA used for
the analysis was NM_005506. The PCR primer sequences are
available from L.D. on request.
Figure 1. Linkage Analysis
Shown in the upper panel: pedigrees used
to map AMRF. Families A and B were previ-
ously clinically described as families 2 and
1, respectively (3), and pedigree C here was
family B in 2. Filled symbols indicate cases
with AMRF. Asterisks indicate individuals
used for genotyping.
Shown in the lower panel: localization of
the critical region on chromosome 4 (see
text). Region I (gray bar) was identified
as homozygous by descent (HBD) in case
A and not shared by the sibling of case A.
In region II, case B shared both haplotypes
identical by descent with unaffected sib-
lings, thus excluding this region. Region
III shows the homozygous region of case
C. Region IV (dashed line) shows the de-
duced critical region of 6.6 Mb. The vertical
black line indicates the position of
SCARB2.
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Total RNA was isolated from lymphocytes and lymphoblastoid
cells with the RNeasy kit (QIAGEN) according to the manufac-
turer’s instructions or from fresh blood with the QIAamp RNA
Blood Mini Kit (QIAGEN). We prepared cDNA from the RNA
with Superscript reverse transcriptase (Invitrogen), using 10 ul of
total RNA and oligo dT primer (Promega). Remaining single-
stranded RNA was digested with RNaseH (Promega), and 2 ml of
the cDNA reaction was used in a 50 ml PCR reaction. PCR was
carried out with forward and reverse primers to the human
SCARB2 sequence as follows:
F 50-TTGCTAAAGCTTCATGGGCCGATGCTGCTTCTA-30
R 50-CGAACTGAATTCTTAGGTTCGAATGAGGGGTGCT-30.
PCR was performed with Accusure Polymerase (Bioline). PCR
products were resolved on 1% agarose gels, bands corresponding
to the Limp2 sequence were excised, the DNA was extracted with
QIAquick gel extraction kit (QIAGEN), and the PCR product was
digested with HindIII and EcoRI. They were then cloned in frame
into the pEGFP-C2 vector (Clontech).
For case A and case B, a discrete single band was not seen after
the ﬁrst round of PCR, so the bands were excised, the DNA was
extracted, and this material was used as a template for a second
round of PCR. In both cases, a band at approximately 1.4 kb
(corresponding to the size of SCARB2 cDNA coding region) was
seen. Ligations were transformed into competent E. coli, and
plasmid DNA was extracted with the QIAprep spin mini prep kit
(QIAGEN). Positive colonies were sequenced so that identity of
the PCR product could be conﬁrmed.
Analysis of SCARB2 Protein
Protein used for expression analysis was isolated from lymphoblas-
toid cell lines from cases A and B and their gender-matched
siblings. An amount of 10–25 mg of total protein was then resolved
on 10% SDS-PAGE gels, and the proteins were transferred to PVDF
membranes. Membranes were probed with goat anti-Limp2
antibody (R&D Systems) and then peroxidase-labeled rabbit
anti-goat Ig (Dako) and were developed with the SuperSignal
West Pico Chemiluminescent substrate (Pierce). Membranes
were stripped and reprobed with mouse mAb anti-b-tubulin
(Sigma) as a control for protein loading.
Limp2-Deﬁcient Mice
Limp2-deﬁcient mice were described previously.16 All experiments
using these mice were performed according to approved national
animal-welfare regulations.
Histology
For conventional light and electron microscopic examination, six
Limp2-deﬁcient mice (ages 6–21.5 months) and four age-matched
wild-type (WT) mice were used. Tissues were perfused with Bouin
solution (diluted 20%–25% with PBS) or glutaraldehyde (6%, in
0.1 M phosphate buffer [pH 7.4]). Tissue blocks were processed
for light- and electron-microscopic examination (embedding in
parafﬁn or araldite) according to routine procedures.
Immunohistochemistry on Tissue Sections
Brains and kidneys of mice perfused with 4% paraformaldehyde
(PFA) in 0.1 M phosphate buffer (PB) were incubated in 30%
sucrose in 0.1 M PB for at least 24 hr before preparing free-ﬂoating
cryosections (50 mm). Sections were rinsed in 0.1 M PB andThe Ablocked in 0.1 M PB with 0.2% BSA, 4% NGS, and 0.5% Triton
X-100 for 2 hr at RT. After incubation with the ﬁrst antibody,
sections were rinsed with 0.1 M PB/0.5% Triton X-100 and incu-
bated with secondary ﬂuorescent antibodies (Alexa ﬂuor 488 and
594; Molecular Probes, 1:1000). The primary antibodies used
were Limp2 (1:500) and DAPI (1:1000) for nuclei staining. Immu-
noﬂuorescence was examined by the Zeiss Axiovert 200 M ﬂuores-
cence microscope.
Behavioral Testing
A group of ﬁve Limp2/ and ﬁve wild-type mice (both groups
consisting of two females and three males) were examined in tests
for neuromotor performance and locomotion, exploratory activ-
ity, and passive-avoidance learning. Cage activity was recorded
with a laboratory-built activity logger connected to three infrared
(IR) photo beams. Mice were put individually in 20 3 30 cm2
transparent cages, placed between the photo beams. Activity was
expressed as beam crossings/30 min during a 24 hr interval.
Gait and walking abilities were evaluated for six 1min trials over
2 days (intertrial interval, 1 hr) on a speed- and inclination-
controlled treadmill connected to an electriﬁed grid (PANLAB).
Before testing, each mouse was adapted to the apparatus and
explored it freely for 5 min. The treadmill inclination was set
at 0, 5, and 10 slopes for each trial, with a constant speed of
10 cm/s. Next day, the same slopes were used, but the velocity
was set to 15 cm/s. Mice were placed on the treadmill belt and
had to move forward in order to avoid receiving foot shocks
(0.4 mA). The number of shocks received was counted.
Grip strength was measured with a T shaped bar connected to
a digital dynamometer (Ugo Basile). Mice were placed before the
bar, which they grabbed spontaneously, and gently pulled back-
ward until they released it. Ten measurements were averaged for
each animal. Motor coordination and equilibrium were tested
on an accelerating rotarod (MED Associates). Mice were ﬁrst
trained at constant speed (4 rpm, 2 min) before four test trials
(intertrial interval, 10 min). During these test trials, the rotating
rod accelerated in 5 min from 4 to 40 rpm. Time until they drop-
ped from the rod was recorded (up to the 5 min cutoff).
Open-ﬁeld exploration was examined with a 503 50 cm2 square
arena. Each animal was dark adapted for 30 min and placed in the
arena for 10 min. Movements of the mice in the arena were
recorded with EthoVision video tracking equipment and software
(Noldus). Total path length and corner crossings were included as
measures of ambulatory activity. Entries into the center of the ﬁeld
were included as a measure of conﬂict resolution or anxiolysis. We
also used the same arena to assess social exploration. In the social
exploration condition, a round wire cage with two female mice
was placed in the center of the arena, enabling visual, olfactory,
and limited physical contact with the test mouse. Latency of the
ﬁrst approach and the number of approaches during the 10 min
exploration trial were assessed.
Anxiety-related exploratory behavior was measured with the
elevated plus maze. The maze was located 40 cm above the table
surface. Mice were placed at the center of the maze and were
allowed to explore freely for 10 min. Exploratory activity was
recorded by ﬁve IR beams (four for arm entries and one for open
arm dwell) connected to a computerized activity logger.
Learned passive avoidance and memory abilities were assessed
in the mice with a step-through box, consisting of one small
illuminated compartment and a dark chamber coupled with
a grid ﬂoor. During training, dark-adapted mice (30 min) weremerican Journal of Human Genetics 82, 673–684, March 2008 675
put in the small illuminated compartment of the box. After 5 s,
a sliding door to the larger dark chamber was opened, and entry
latency was recorded. The door was closed as soon as all four
feet were on the grid ﬂoor, and a slight foot shock (0.3 mA, 1 s)
was delivered with a constant current shocker (Med Associates).
Retention was tested 24 hr later with the same procedure, with
the exception that the animals did not receive any shock. Entry
was recorded up to a 300 s cutoff.
Results
Genomic Mapping of AMRF
Homozygosity mapping of the known consanguineous
family A was carried out with multipoint analysis with
MERLIN7 and identiﬁed 21 regions with evidence for
homozygosity by descent (HBD) sharing in case A. The
boundaries of these candidate regions were determined
by ﬂanking heterozygous SNPs. The regions ranged in
size from 13 markers spanning 0.18 cM to 1103 markers
spanning 62.4 cM. The average length of the regions was
12 cM, encompassing 213 markers.
Pairwise identical by descent (IBD) sharing probabilities
were calculated for all possible pairs of affected and
unaffected siblings in each family. Candidate regions
were eliminated or shortened if any of the unaffected
siblings shared both haplotypes IBD with their affected
sibling. This strategy assumes locus homogeneity and com-
plete penetrance but makes no assumption about allelic
homogeneity and allows for compound heterozygote
affecteds. After application of this strategy, 12 regions
remained with some of these regions now reduced in size
(average length¼ 6.2 cM, spanning an average of 84 SNPs).
Given the apparent rarity of this disease, it was possible
that only a single disease-causingmutation arose in a given
population. Under the assumption of allelic homogeneity
within families, cases B and C would also be homozygous
for their private mutations caused by unknown inbreeding
loops in the ancestry of the two families. Two methods
were used to look for regions ﬁtting this description. The
ﬁrst was to treat the parents of the two cases as second
cousins and to conduct homozygosity analysis with these
modiﬁed pedigrees. The second method is based on the
observation that, if there were a single pathogenic muta-
tion in a given population, the cases in the outbred
families would be homozygous for all SNPs in the marker
haplotype surrounding the mutation.
Regions ﬁtting this description were identiﬁed as long
runs of homozygous markers in the affected individuals
from the outbred families. In family C, two regions were
identiﬁed that overlapped with the set of regions identiﬁed
by these methods and the set of 12 previously isolated
candidate regions. A 5.3 cM critical region, which includes
175 SNPs, was found on chromosome 4. The second region
on chromosome 20 produced a candidate intersection
region covering 3.0 cM but only containing 13 SNPs.
We further investigated these two regions for true HBD
by examining four polymorphic microsatellite markers in676 The American Journal of Human Genetics 82, 673–684, Marchthe chromosome 4 critical region and three in the chromo-
some 20 region. None of the three microsatellite markers
in the region on chromosome 20 were homozygous in
case C, indicating that this region was indeed only homo-
zygous by state for the SNP markers and not HBD. The
microsatellites in the chromosome 4 region were homozy-
gous in cases A and C. This observation is consistent with
the hypothesis that case C inherited this haplotype HBD
through an unobserved (and possibly distant) inbreeding
loop.
By using a multipoint maximum-likelihood method9 to
test for the possibility of relatedness, we estimated that the
parents of case C were ﬁfth degree relatives (e.g., second
cousins, LOD ¼ 2.99, p value ¼ 0.0001). Both parents of
case C had ancestors from Tasmania, the island state of
Australia. It is estimated that approximately two-thirds
of Tasmania’s current population of 500,000 are individ-
uals descended from approximately 10,000 women of Brit-
ish origin who had migrated to the state by 1850.9
Thus, a 5.3 cM critical region (equivalent to 6.6 Mb) was
deﬁned by the overlap on chromosome 4q13-21 of regions
in which case A and case C were HBD, narrowed slightly by
a family B region in which the affected shared a segment
IBD with an unaffected sibling (Figure 1).
Expression-Array Analysis
The critical region on 4q13-21 contains 66 known genes of
which approximately half are expressed in both the brain
and kidney. In order to prioritize candidate genes for
sequencing, we hypothesized that the mRNA of the causa-
tive gene would be downregulated in affected subjects,
possibly because of mutations causing RNA instability.
We therefore analyzed RNA from lymphoblastoid cell lines
derived from two living affected subjects and from
a healthy gender-matched sibling of each (families A and
B) with Affymetrix U133 Plus2 arrays.
The data were analyzed with a two-way empirical Bayes
ANOVA approach for detecting signiﬁcant differences
between affected and unaffected individuals adjusted for
differences between families (see Materials and Methods).
Initial analysis of the data set on a genome-wide basis
showed major differences in expression of a number of
genes related to immune regulation. For example IGHG1,
IGHV1-69, and IL16were found to be signiﬁcantly disregu-
lated in affected individuals (data not shown). This was not
surprising because the two affected individuals had under-
gone renal transplantation and were taking immunosup-
pressive drugs. Analysis was subsequently conﬁned to the
probe sets in the 6.6 Mb region deﬁned by our mapping.
SCARB2 (Scavenger Receptor B2) emerged as the leading
candidate. It was downregulated ~2-fold in the affected
subjects compared to their healthy siblings (p < 0.001,
Table 1). This was the probe set closest to the 30 end, in
which RNA degradation is least likely to have occurred
and was therefore the most informative in indicating
gene downregulation. Another probe set to the SCARB2
gene also showed differential downregulation in the2008
affected individuals when compared to their unaffected
siblings.
Mutational Analysis of SCARB2
We hypothesized from the clinical genetics (known
consanguinity in family A) and the SNP-chip mapping
that cases A and C would have mutations HBD, whereas
case B would be a compound heterozygote.
We identiﬁed different homozygous mutations in cases
A and C, consistent with our prediction. Case A had a
homozygous splice-site mutation (c.1239þ1G/T).
RT-PCR analysis showed that this mutation leads to reten-
tion of intron 10 and the subsequent insertion of 20
amino acids and premature truncation of the protein at
residue 433. The mutation in case C (c.435_436insAG
W146SfsX16) results in a frameshift predicted to truncate
the protein to 160 amino acids. From the sequence trace,
this mutation appears homozygous, as predicted by the
haplotype analysis, although the paternal DNA was not
available for direct conﬁrmation of carrier status. In case
B, a heterozygous frameshift mutation (c.296 delA
N99IfsX34) inherited from his unaffected mother was
identiﬁed that predicts truncation of the protein to 131
amino acids, but no second mutation was found in the
coding regions (Figure 2). RT-PCR analysis of RNA ex-
tracted from lymphocytes from case B showed the pres-
ence of wild-type cDNA as well as a number of additional
RNA species compared to a single WT product from unaf-
fected controls (data not shown). Sequencing of the addi-
tional multiple cDNA products suggested that a number
of different exon-skipping events were occurring in case
B, but we were unable to deﬁnitively characterize these.
In our sequencing of the genomic DNA of this patient,
we noted that he carried a number of intronic sequence
variants not found in the other patients or reported in
Table 1. The Ten Most Differentially Expressed Probe
Sets when Analysis Was Limited to the Critical Region
on Chromosome 4
ID Symbol logFC AveExpr t FDR B
224983_at SCARB2 1.109 4.26 10.07 0.001 4.32
235638_at RASSF6 1.070 5.84 8.34 0.002 3.04
227119_at CNOT6L 0.960 3.68 6.99 0.005 1.81
204533_at CXCL10 1.730 4.32 5.39 0.019 0.06
225548_at SHRM 0.674 2.76 5.38 0.019 0.05
226153_s_at CNOT6L 0.840 4.75 5.21 0.020 0.16
235653_s_at THAP6 0.424 4.26 5.08 0.020 0.32
201646_at SCARB2 0.741 2.22 4.98 0.020 0.45
208840_s_at G3BP2 0.354 7.86 4.16 0.053 1.55
202770_s_at CCNG2 0.550 8.17 4.02 0.058 1.76
‘‘logFC’’ is the log2 fold change in expression between affected subjects and
their unaffected siblings (a value of 1 indicates a 2-fold decrease in the
affected). ‘‘FDR’’ is the upper bound for the expected false discovery rate
after adjustment for multiple testing across the 98 probe sets in the critical
region. ‘‘AveExpr’’ is the average log2 expression level across all subjects, ‘‘t’’
is the moderated t statistic testing differential expression, and ‘‘B’’ is the
log-odds of differential expression. Note that some genes (including
SCARB2) have two probe sets represented.The ASNP databases. Together, this suggests that the patient’s
second SCARB2 allele may contain cryptic splice-site recog-
nition sequences leading to aberrant RNA splicing. This
suggests that the second mutation is outside the coding
region, perhaps affecting translation or RNA stability,
because no detectable SCARB2 protein is produced (see
below) yet mRNA is present.
We subsequently identiﬁed a SCARB2mutation in one of
the original AMRF families fromQuebec (family F in 2). The
three affected members are deceased, and no DNA is
available for testing, but obligate carriers of this autoso-
mal-recessive disorder have the nonsense mutation
c.862C/T, Q288X, which is predicted to prematurely ter-
minate the protein or lead to nonsense-mediated RNA de-
cay of the transcript. Study of another previously reported
Canadian case, without French-Canadian ancestry (case
PO3 in 2) revealed a frameshift mutation (W146SfsX16),
identical to case C. Parental DNA is not available for test-
ing, so we are unable to distinguish whether the mutation
is homozygous or hemizygous with deletion of a segment
of the chromosome 4 homolog that would normally bear
the second pathogenic allele.
In order to determine whether SCARB2 mutations were
associated with other forms of inherited proteinuria, we
studied eight families with nonsyndromic focal and
segmental glomerulosclerosis (FSGS, ‘‘steroid-resistant
nephrotic syndrome’’) and ﬁve with minimal-change glo-
merulonephritis (‘‘steroid-sensitive nephrotic syndrome’’).
Inheritance was consistent with autosomal-recessive dis-
ease in four families with FSGS and in two with minimal-
change glomerulonephritis. NPHS2 mutations, which are
the most common known cause of inherited FSGS, had
been excluded previously. In addition, six patients with
thin-basement-membrane nephropathy (deﬁned on renal
biopsy) and proteinuria >500 mg/day and three
individuals from non-Alport families with haematuria
and proteinuria (two of whom were consanguineous)
were screened for SCARB2 mutations. No mutations were
identiﬁed in the 22 index cases. Five variants were found
(coding region variants c.445G/A, c.475A/G, and
c.1265C/T; intronic variants c.1437þ22G/A, c.995-
49_53 delCAGCT) and were regarded as unlikely to be
pathogenic because they did not segregate with disease,
were found in controls, or were intronic.
Western Blots of SCARB2
Western blots of cell lysates prepared from EBV-trans-
formed lymphoblastoid B cell lines from the two affected
living subjects (A and B), and one unaffected sibling for
each of the subjects were probed with antibodies to
Limp2 (the mouse ortholog of human SCARB2) (Figure 3).
The antibody was validated by transfection of GFP-tagged
human SCARB2 cDNA into HEK293 cells; this was followed
by western blotting (data not shown). SCARB2 was easily
detectable in lymphoblastoid cell lines from healthy
siblings as a single band at 75–80 kDa but was undetectable
in both affected subjects.merican Journal of Human Genetics 82, 673–684, March 2008 677
Pleiotropic Effects of SCARB2/Limp2 Deﬁciency
in Human and Mouse
A mouse deﬁcient in Limp2 was developed previously,16
independent of clinical research on AMRF, and also has
a phenotype predominantly involving the nervous system
and kidney. The main phenotypic features were cochlear
deafness, demyelinating peripheral neuropathy, and
hydronephrosis due to ureteric-pelvic junction obstruc-
tion.16,17We re-examined available AMRF cases in the light
of observations in the mouse and reinvestigated the
Limp2/ mouse phenotype informed by observations in
the patients (Table 2).
Deafness has not been reported in AMRF patients.
Audiograms on cases A and B showed minor bilateral
impairment at high frequencies, of doubtful signiﬁcance.
Patients have no clinical evidence of a sensory, motor, or
autonomic peripheral neuropathy. Nerve-conduction
studies previously reported in six patients were normal or
showed mild abnormalities suggestive of a predominant
Figure 2. SCARB2 Mutations
Genomic structure of the SCARB2 gene and
the position of the mutations found in the
AMRF cases. The sequencing chromato-
grams indicate the mutations found in
the affected individuals or in a carrier,
and the predicted effects of the mutations
on the SCARB2 protein are illustrated
below. ‘‘WT’’ refers to an individual lacking
a mutation, ‘‘WT/’’ refers to a heterozy-
gote, and ‘‘/’’ refers to an individual
homozygous for a mutation.
axonal neuropathy.2,18 Nerve-con-
duction studies on case A were
normal, and case B had evidence of
a mild sensorimotor neuropathy.
Whether this neuropathy is a core
feature of AMRF or is due to renal
failure and its treatment remains
uncertain.
In the brains of AMRF patients,
there is accumulation of autoﬂuores-
cent pigment granules particularly in
the laminae I and II of the cerebral
cortex, basal ganglia, and in the Pur-
kinje cell layer of the cerebellar
cortex2 (Figure 4A). Examination of
the brain in Limp2-deﬁcient mice
revealed abnormal autoﬂuorescent
cytoplasmic inclusions (not shown)
in laminae II, III, and Vof the cerebral
cortex and in Purkinje cells, in some
Bergmann astrocytes, and within the
molecular layer of the cerebellum.
Semithin sections and electron
microscopy showed that the inclusions were intracellular
(Figures 4B–4I). The human studies, performed on post-
mortem material, suggested that the granules were extra-
neuronal and probably in astrocytes.2 Immunohistological
studies of cerebellum with Limp2 antibodies showed that
the protein was concentrated in the Purkinje cell layer of
normal mice and absent in Limp2/ animals (Figure 4J).
In Limp2/ mice, myoclonic jerks or epileptic seizures
were never observed. Cage-activity recordings revealed
slight hyperactivity in the Limp2/ animals compared
to controls. Both Limp2/ and wild-type animals showed
an initial explosion in exploratory activity upon their
introduction into the cages, but the former were overall
much more active between 21:00 p.m. and 5:00 a.m.
(i.e., during most of their active phase). When placed on
a tabletop, Limp2/ mice clearly displayed ataxic gait,
but treadmill gait performance was only decreased on the
high-velocity trials (15 cm/s, not shown). Limp2/ mice
made more errors (8.2 5 1.8 shocks) than wild-type mice
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(4.0 5 0.5 shocks) at 5 and 10 treadmill inclination
(one-tailed t test, p < 0.05). Grip-strength measurements
were normal in Limp2/ mice (660 5 36 mN) compared
to controls (688 5 27 mN, not shown), but their perfor-
mance on the rotarod test was severely impaired (Figure 5).
On all trials, Limp2/ animals fell from the rod much
sooner than controls did (repeated-measures ANOVA,
effect of genotype, F1,8 ¼ 23.3, p ¼ 0.001).
In contrast, Limp2/ mice performed normally on the
remaining exploratory and learning tests, indicating that
their ataxia might be an isolated impairment (Table 3). In
accordance with the cage-activity measures, Limp2/
mice were more active than controls in the open-ﬁeld
test (as indicated by their path length and corner-crossing
measures), but differences did not reach signiﬁcance. On
the other hand, measures related to conﬂict resolution
(i.e., latencies and number of approaches to the center)
were very similar between genotypes; additionally, in the
social-exploration task, Limp2/ mice showed virtually
the same exploratory responses as controls (Table 3).
Limp2/ mice also displayed normal elevated-plus-maze
Figure 3. Western Blots with Lymphoblastoid Cell Lines from
Cases A and B and Their Unaffected Siblings
SCARB2 was probed with a polyclonal goat antibody to Limp2 and
is shown in the samples from the two siblings as a band at 75–80
kD; it was absent in the two cases. b-tubulin is shown in all four
subjects at ~50kD as a control.performance as we observed similar open-arm exploration
to controls. Finally, passive-avoidance learning ability was
not altered in the Limp2/ group as demonstrated
by closely matched step-through latencies between
Limp2/ and wild-type mice.
One aspect of the renal pathology in Limp2-deﬁcient
mice is a hydronephrosis due to pelvi-ureteric obstruction
that occurs unilaterally or bilaterally in most but not all
mice. The obstruction was accompanied by hypertrophy
of ureteric smooth muscle and epithelial metaplasia. The
latter was associated with a disturbed apical expression of
uroplakin suggesting an impairment of membrane trans-
port processes.16 Kidneys in AMRF patients are small,
with no evidence of obstruction, but pathological exami-
nation of the human ureter to ﬁnd subtle mucosal thicken-
ing has not been possible to date. The renal lesion in AMRF
is severe focal glomerulosclerosis sometimes with glomeru-
lar collapse presenting as proteinuria with acute or sub-
acute renal failure (Figures 6A and 6B). Limp2-deﬁcient
mice have proteinuria, which was previously regarded as
secondary to hydronephrosis.16 Examination of nonhy-
dronephrotic kidneys showed deﬁnite glomerular lesions
with mesangial hyper cellularity evident by light micros-
copy and severe effacement of foot processes at electron
microcopy (Figures 6C–6G), but without frank changes of
glomerulosclerosis. In contrast to other lysosomal-mem-
brane proteins such as LAMP1 (data not shown), Limp2
is highly expressed in glomeruli of wild-type mice but is
absent in Limp2-deﬁcient mice (Figure 6H).
Discussion
The discovery of mutations in SCARB2 responsible for
AMRF highlights the power of recent advances in high-
throughput genotype and expression platforms for the
identiﬁcation of genes responsible for rare autosomal-
recessive diseases. A combination of SNP-chip linkage
mapping, examination of haplotype sharing, and microar-
ray-expression analysis on a sample of three unrelated
individuals with AMRF led to the prioritization of SCARB2
as the leading candidate gene. This stepwise elimination of
candidate regions represents a paradigm for other recessiveTable 2. Pleiotropic Effects of SCARB2/Limp2 Deficiency in Man and Mice
Action Myoclonus Renal Failure Syndrome Limp2-Deficient Mouse
Myoclonus and seizures Central feature: progressive and severe Absent
Ataxia Moderate Mild
Hearing Normal hearing and audiograms Deaf from 3 months
Peripheral nerves Clinically normal; nerve-conduction studies
in some subjects show evidence of a mild
sensorimotor neuropathy
Demyelinating neuropathy
Brain pathology Intracellular storage, apparently
extra-neuronal
Storage in neurons and astrocytes
Pelvi-ureteric obstruction Absent Present in most mice
Glomerular pathology Central feature: severe focal
glomerulosclerosis with glomerular collapse
Minor mesangial proliferation, podocyte
effacement; no glomerulosclerosis
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Figure 4. Neuropathology of AMRF and Limp2-Deficient Mice
(A) Human cerebellar vermis (autopsy sample; case C). Magenta-colored granules are seen between intact Purkinje cells (PAS stain; the
scale bar represents 0.05 mm).
(B–E) Light microscopy of Limp2/ brain in 16-month-old mice (semithin sections, toluidine blue). Cerebellar cortex of Limp2/mouse
(B) shows all Purkinje cells (PC) as well as some neurons and glial cells in the molecular layer (ml) with numerous cytoplasmic inclusions
(dense bodies) (arrowheads). In control wild-type mice (C), no inclusions are seen in the Purkinje cells (marked with asterisks), granular
layer (gl), or ml. Sections of cerebral cortex from Limp2/ show similar cytoplasmic inclusions that are in neuronal perikarya of laminae
2/3 and 5 (D) and that are absent in the cerebral cortex of wild-type mice (E). Layer 5 (L5) is shown. Scale bars represent 50 mm.
(F–I) Electron microscopy of Limp2/ mouse brain. One Purkinje cell shown at increasing magnifications from left to right. The boxes
indicate the region shown at higher magnification. The osmiophilic inclusions were most frequently observed within the perikarya and
only very rarely within dendrites (not shown). The membrane-limited inclusions contain homogeneously granular material, some lipid
droplets, and occasionally some lamellar structures. Scale bars represent 10 mm, 5 mm, 1 mm, and 0.5 mm, respectively.
(J) Immunohistological studies of mouse cerebellum. Wild-type cerebellar cortex (WT) is shown with nuclei stained with DAPI in blue.
Limp2 is shown in green and is concentrated in the Purkinje cell layer (the scale bar represents 200 mm). The inset shows knockout (KO)
with absence of Limp2 in the Purkinje cell layer.Mendelian disorders with few affected individuals. This is
a powerful approach for recessive-disease families with
known or likely inbreeding loops in their ancestry.19
As demonstrated here, gene-expression studies can also
aid in prioritizing genes for sequencing in which linkage
mapping leads to an interval with a large number of candi-
date genes. This strategy is particularly applicable for reces-
sive diseases, such as AMRF, for which a knockdown or
knockout effect could produce a detectable difference in ex-
pression between cases and controls. This is one of the ﬁrst
studies thathave successfully usedgene-expression analysis
to prioritize the best candidate gene for a recessive disease.
Previous applications to genetic disorders have included
a dominant disease with low penetrance20 and a complex
disease.21 Success hinges on gene expression in the primary
tissues of interest (in this case, brain and kidney) beingmir-
rored in lymphocytes, when the primary tissues are not
accessible. SCARB2 has low, but detectable, expression in
lymphocytes. In AMRF, the analysis of lymphocyte expres-
sion was potentially compromised by the immunosuppres-
sive therapies that patients were undergoing as part of their
renal-transplant therapy. An essential point is that the dif-
ferential-expression analysis does not need to be carried
out genome wide. With the linkage-analysis data, only
probe sets in 66 geneswere assessed for expression changes.
The success of the differential-expression study in identify-680 The American Journal of Human Genetics 82, 673–684, Marching SCARB2 reliedonmicroararray-analysis tools thatmain-
tain good precision even for lowly expressed genes and that
can evaluate statistical signiﬁcance reliably with small
numbers of arrays. SCARB2wouldnothavebeen top ranked
from themicroarray study on the basis ofmore naive statis-
tical criteria such as fold change or ordinary t tests.
These data establish mutations in SCARB2 as the major
cause of AMRF. The same mutation responsible for AMRF
in case C was also detected in a Canadian AMRF patient,
highlighting that this mutation is likely to be an ancestral
Anglo-Celtic mutation. The absence of mutations in other
familial nephropathies suggests SCARB2mutations may be
speciﬁc for AMRF.
SCARB2 is an ancestral gene and has a ortholog in Caeno-
rhabditis elegans. The human and mouse SCARB2/Limp2
share 84% nucleotide and 85% amino acid identity.
SCARB2 encodes a 478 amino acid glycoprotein located
in lysosomal membranes.22,23 The gene is expressed in
a range of tissues including brain and kidney. The roles
of SCARB2 are not well understood, but it is thought to
play a role in the biogenesis and maintenance of endoso-
mal and lysosomal compartments.24,25 The protein has
an N- and C-terminal transmembrane domain and a large,
well conserved CD36 domain.
Eachof theSCARB2mutations found intheAMRFpatients
fall within the CD36 domain (Figure 2). SCARB2/Limp22008
is an abundant lysosomal-membrane protein. SCARB2/
Limp2 may sometimes be expressed at the cell surface,
but in the majority of cells, the steady-state distribution
is intracellular.25 It may have pleiotropic functions as
shown by the heterogeneous cellular pathology in mice16
and humans (this paper) deﬁcient of Limp2/SCARB2, in-
cluding a role in lysosomal biogenesis.24 Pleiotropy may
be conferred by a gene product having multiple molecular
functions or by multiple consequences of a single molecu-
lar function.26 Genes with pleiotropic effects are, in gen-
eral, under strong stabilizing selection, but there may be
compromises among adaptation of different traits because
changes that are beneﬁcial in one tissue may be deleterious
in another.26,27 Dysfunction of SCARB2/Limp2 has maxi-
mum phenotypic effect on the nervous system and kidney,
but the pathology is different, showing storage in the brain
but not in the kidney. Moreover, across species, brain stor-
age is predominantly intraneuronal in mice but extra-
neuronal in man. The renal pathology is glomerular in
man but in mice predominantly affects the urothelium
with subtle glomerular lesions.
The renal lesions seen in human and mouse kidneys
with SCARB2/Limp2 mutations differed. Pelvi-ureteric ob-
struction, as observed in Limp2-deﬁcient mice, was not
seen in humans. Glomerular lesions were found in both,
but of quite different severity. Whereas the human glomer-
uli showed collapsing glomerulopathy, the most severe
variant of FSGS, this was not seen in the Limp2/ mice.
The mice did have proteinuria of presumed glomerular or-
igin associated with foot-process effacement.
Mutations of a lysosomal protein suggest a new mecha-
nism for the genesis of proteinuria and FSGS. Inherited
Figure 5. Rotarod Testing of Limp2/ and Wild-Type Mice
Accelerating rotarod performance in wild-type (black bars) and
Limp2/ (white bars) mice. On each of the 5 min trials,
Limp2/ mice were unable to balance on the rod quite as long
as wild-type (control) mice, and this demonstrates the ataxia
and neuromotor impairment in the Limp2-deficient group. Data
are means and SEM; asterisks indicate significance of difference
with control values (post hoc Fisher LSD), *p < 0.05, **p < 0.01,
and ***p ¼ 0.001.The Aforms of FSGS that involve proteins expressed exclusively
or strongly in the podocyte have previously been
described. Many affect podocyte structure, and in particu-
lar, the maintenance of the slit diaphragm,28 and one
affects a phospholipase (PLCE1) expressed in podocytes.29
The renal lesion in AMRF differs from the other inherited
forms of FSGS in that it is a much more severe histological
variant. SCARB2/Limp2 is expressed in podocytes (data
not shown), although none of the proteins associated
with congenital FSGS have a known role in lysosomal
function, and it is not known whether SCARB2 interacts
with any of them. A hypothesis to explain how abnormal
lysosomal function due to lack of SCARB2 results in pro-
teinuria is that altered recycling or degradation of one or
more of these proteins contributes to glomerular damage.
Evidence that SCARB2mutations contribute to the path-
ogenesis of collapsing glomerulopathy has implications for
other diseases. Collapsing glomerulopathy is a FSGS
variant that is associated with prominent podocyte hyper-
plasia and is commonly seen in HIV nephropathy. Nef is
the protein critical for FSGS in HIV nephropathy.30 Inter-
estingly, nef possesses a similar intracellular sorting motif
to one present in SCARB2. It is possible that nef interacts
with proteins that usually bind SCARB2, thereby giving
rise to lysosomal abnormalities and changes in podocyte
function.
Progressive myoclonus epilepsy (PME) can be caused by
a variety ofmolecular lesions. These includemitochondrial
tRNA mutations and autosomal-recessive mutations in
Table 3. Cage and Exploratory Activity and Passive-
Avoidance Learning in Limp2-Deficient Mice and Controls
Test Measure Limp2þ/þ Limp2/ p Value*
Cage activity
(counts/24 hr)
61355 851 103425 1225 p ¼ 0.022**
Open Field
Path length (cm) 11975 265 27315 612 p ¼ 0.15
Corner crossings 375 9 63.85 14.6 p ¼ 0.17
Latency of center entry (s) 2845 130 1665 110.7 p ¼ 0.5
Number of center entries 4.85 3.2 11.65 5.2 p ¼ 0.3
Social Exploration
Latency of center entry (s) 1725 109 1715 113 p ¼ 0.99
Number of center entries 115 5 145 5 p ¼ 0.7
Elevated Plus Maze
Percentage of time
in open arms
335 8 325 4 p ¼ 0.9
Percentage of counts
in open arms
355 5 265 4 p ¼ 0.21
Passive-Avoidance Learning
Step-through latency (s) 1565 59 1595 57 p ¼ 0.97
All data are means5 SEM.
* Values are determined by two-tailed t test except where indicated.
** This value is determined by repeated measures ANOVA, effect of geno-
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Figure 6. Glomerular Pathology in
AMRF and Limp2-Deficient Mice
(A and B) Human glomerular pathology.
Representative renal cortex (A) of human
case C with AMRF showing an almost totally
sclerosed glomerulus (arrow) because of
global collapse and two glomeruli showing
the early phases of collapse and sclerosis.
Higher power (B) of the two glomeruli in
the early phases of capillary collapse with
partially obliterated lumina and prominent
epithelial cells caused by hypertrophy and
hyperplasia (silver methernamine-Marson’s
trichrome) is shown. Scale bars represent
50 mm.
(C–F) Light microscopy of Limp2/ mice.
Glomerulus of a wild-type (WT) mouse
aged 16 months with the typical tissue
structure (C) compared to Limp2/ (KO)
mouse (D), with arrowheads indicating an
expanded messangium (semithin sections,
toluidine blue). The same wild-type animal
with silver stain for highlighting extracel-
lular matrix and basal membranes (E) com-
pared to the Limp2/ mouse (F) with
a mesangium that is expanded (arrow-
heads) is shown. Scale bars represent
50 mm.
(G) Electron microscopy of Limp2/ (Gi–
Giii) and wild-type (G iv–Gv) mice. Images
show effacement of the foot processes of
the podocytes (blue arrowheads) and
thickening of the glomerular basal mem-
brane (green arrows) in Limp2/ (KO)
mice compared to normal podocyte mor-
phology and basement-membrane thick-
ness in wild-type (WT) animals. Scale bars
represent 10 mm (Gi and Giv), 5 mm (Gii),
and 2.5 mm (Giii and Gv).
(H) Immunohistological studies of mouse
renal cortex. The overview shows wild-
type cortex with nuclei in blue (DAPI) and Limp2 in green; glomeruli are indicated by arrows (scale bar represents 200 mm). High-mag-
nification insets of glomeruli show Limp2 in wild-type animals but absent in knockout animals.a variety of genes including an intracellular protease inhib-
itor (Cystatin B) and molecules that lead to intracellular
storage of glycoproteins (EPM2A and EPM2B) or lipofus-
cin-like material (CLN2-8).31 The addition of SCARB2 to
this list further highlights the importance of lysosomal
mechanisms in the genesis of PME. The ﬁnal common
pathway for the genesis of the PME syndrome by such
diverse molecular causes is unknown but appears to
involve the cerebellum and probably the rubral and olivi-
ary connections. The prominent involvement of the cere-
bellum in the storage process in both human AMRF and
the Limp2/ mouse supports this. Interestingly, whereas
both species have ataxia, myoclonus was not seen in the
mouse. Similarly, in the prototypic PME, Unverricht-Lund-
borg disease, because of deﬁciency in cystatin B, the mouse
model has prominent ataxia, but seizures and myoclonus682 The American Journal of Human Genetics 82, 673–684, Marchare speciﬁc to certain genetic backgrounds.32,33 Moreover,
cystatin B is known to be associated with lysosomes, at
least at early stages of differentiation,34 so deﬁciencies in
SCARB2 and cystatin Bmight act via a similar cellular path-
way in causing PME.
The accumulation of storage material in brain is consis-
tent with the known role of SCARB2/Limp2 as a lysosomal
protein,22,23 perhaps affecting intracellular transport or
endosome recycling. Lysosomes have a crucial role in
autophagy, a process recently believed to be very impor-
tant in neurodegenerative diseases.35 SCARB2/Limp2
might have a role in physiological autophagy, and its deﬁ-
ciency could thus lead to accumulation of normally
recycled proteins or organelles manifesting as inclusions.
Moreover, the neuropathology of SCARB2/Limp2 deﬁ-
ciency bears some resemblance to that of the family of2008
neuronal ceroid lipofuscinoses in which a variety of
lysosomal-related proteins are deﬁcient36 and disturbed
autophagy has been demonstrated;37–39 indeed, AMRF
can be mistaken for the adult form (Kufs disease).40 Inter-
estingly, Limp2 was also recently described as a receptor
for b-glucocerebrosidase, the enzyme that is deﬁcient in
Gaucher disease.41 The lack of the Limp2 receptor in
mice caused a missorting of the majority of glucocerebrosi-
dase to the extracellular space, and the lysosomal level of
this enzyme was found to be severely reduced. This lack
of lysosomal b-glucocerebrosidase was apparently not
sufﬁcient to cause a robust Gaucher-like phenotype in
Limp2-deﬁcient mice. It needs to be elucidated whether
the observed neuronal storage in Limp2-deﬁcient mice is
associated with a defect in glucosylceramide metabolism.
In man, however, the type 3 form of Gaucher disease
(MIM 231000) does have progressive myoclonus epilepsy
as a key part of the phenotype.42 Finally, SCARB2/Limp2
has also been shown to have an extra-lysosomal role in
the intercalated disc of the cardiac myocyte,43 so whether
the renal lesions are the consequence of lysosomal or
extra-lysosomal dysfunction needs to be determined and
will be essential for designing therapeutic strategies.
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